Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™.
- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Maximum Tolerated Dose (MTD) study in Sprague-Dawley Rats for Probudur™.
- Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications.
- Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain.
- The study was designed to determine the MTD of free bupivacaine, Probudur, and Probudur plus free bupivacaine when administered as a single subcutaneous injection to the wound.